Xcelience, IriSys in Alliance

Xcelience and IriSys have entered into a business alliance agreement to advance the ability to streamline access to CMC and regulatory expertise for North American pharmaceutical and biotechnology companies.

“IriSys has considerable experience moving compounds from early research to Phase I/II clinical trials in addition to offering full regulatory and strategic planning services,” said Derek Hennecke, chief executive officer and president of Xcelience. “This alliance provides a unique opportunity to leverage these strengths in conjunction with our own in a way that minimizes client risk, and maximizes client accessibility to the strategic locations of each company on the east and west coasts of the U.S.”

“Xcelience has a solid industry-wide reputation for accelerating the early drug development process; their particular solid dosage form technology expertise in filling an active pharmaceutical ingredient into capsules and their outstanding project management system are certainly complementary to IriSys,” said Gina Stack, president and chief executive officer of IriSys.